BeyondSpring Inc. has announced its Q1 2025 financial results and provided an update on its clinical programs, highlighting the early efficacy of its drug Plinabulin in treating metastatic non-small ...

CheckMate 9LA showed a 26% overall survival benefit for metastatic NSCLC patients treated with nivolumab and ipilimumab plus ...

BeyondSpring presents Phase 2 data showing Plinabulin's potential in metastatic NSCLC after PD-1/L1 therapy, with promising survival rates. BeyondSpring Inc. announced promising interim results from ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough ...

About 40% of people with non-small cell lung cancer (NSCLC)—a type of cancer that begins in the tissues of your lungs—have metastatic disease at the time of their diagnosis. Metastatic NSCLC refers to ...

LUND, SE / ACCESS Newswire / October 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) (STO:BINV), a biotech company focused on the discovery and development of novel and ...

Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in First-Line Treatment of Patients with Advanced ...

Summit Therapeutics Inc. (SMMT) recently announced that it had created a collaboration agreement with Pfizer (PFE) for both to advance clinical studies of ivonescimab together with antibody-drug ...

New Study Introduces a Personalized Therapy Selection Approach in NSCLC Poised to Transform Treatment Decisions Cellworks Group Inc., a leader in Personalized Therapy Decision Support and ...

TT125-802 is a small molecule CBP/p300 bromodomain inhibitor that shows clinical activity as single agent in solid tumors, including advanced EGFR-mutated and KRAS-G12C-mutated non-small cell lung ...